Study on the clinical effect of losartan combined perindopril on treating early diabetic nephropathy

Objective: To investigate the effect and mechanism of losartan combined perindopril on the patients with early diabetic nephropathy.Methods: All of 80 cases with early diabetic nephropathy were randomly divided into four groups:routine therapy(n=20),perindopril(n=20),losartan(n=20) and combination group(n=20).The patients in above-mentioned four group had been treated with routine drugs,perindopril(4 mg/d)+routing drugs,losartan(50 mg/d)+routing drugs and perindopril(4 mg/d)+losartan(50 mg/d)+routine drugs respectively for eight weeks,and their UAL,urinary transforming growth factor-β(TGF-β),urinary endothelin(ET),renal function and serum lipid profile were measured.In addition,20 cases healthy volunteer served as a normal control group. Results: Before treatment,the levels of UAL,urinary TGF-β and urinary ET did not differ significantly among the four groups,but the indexes mentioned above were significantly higher than normal control group(P0.05).Eight weeks later,the levels of urinary MA,urinary TGF-β and urinary ET in perindopril,losartan and combination group were significantly lower than that before treatment.(P0.05),and combination treatment had more descendent indexes mentioned above than losartan or perindopril treatment alone. Conclusion: Combination of losartan with perindopril can significantly decrease the excretion of UAL,urinary TGF-β and urinary ET compared with the agents used separately in the early diabetic nephropathy and delay progress of the disease.